Cancer and the immune response: improving the odds.
Medscape General Medicine.
Sara M
SM
Mariani
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D002460:Cell Line; D006801:Humans; D007116:Immunization, Passive / Q000379:methods / Q000639:trends; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000639:trends; D020014:K562 Cells; D007938:Leukemia / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D018396:Mucin-1 / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control; D018739:Oncogene Proteins v-erbB / Q000276:immunology / Q000627:therapeutic use; D016601:RNA-Binding Proteins / Q000276:immunology / Q000627:therapeutic use; D017452:Receptors, IgG / Q000276:immunology; D000069283:Rituximab; D000068878:Trastuzumab; D025721:WT1 Proteins / Q000276:immunology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; C473444:L523S protein, human; D018396:Mucin-1; D018739:Oncogene Proteins v-erbB; D016601:RNA-Binding Proteins; D017452:Receptors, IgG; D025721:WT1 Proteins; D000069283:Rituximab; D000068878:Trastuzumab